Overview

A Study Investigating the Relationship Between the Development of Laronidase Antibody and Urinary GAG (Glycosaminoglycan) Levels in Aldurazyme® Treated Patients

Status:
Completed

Trial end date:
2007-05-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine whether the development of antibodies to laronidase in patients with MPS I receiving Aldurazyme® impairs the clearance of GAG substrate.

Phase:

Phase 4

Details

Lead Sponsor:

Genzyme, a Sanofi Company

Collaborator:

BioMarin/Genzyme LLC

Treatments:

Antibodies